Statute Details
- Title: Health Products (Clinical Research Materials) Regulations 2016
- Act Code: HPA2007-S332-2016
- Type: Subsidiary legislation (sl)
- Enacting Authority: Health Sciences Authority (HSA), with Minister for Health approval
- Authorising Act: Health Products Act (Cap. 122D), sections 71 and 72
- Commencement: 1 November 2016
- Current Version: Current version as at 27 Mar 2026
- Key Parts: Part 1 (General); Part 2 (Exceptions); Part 3 (Manufacture and Import); Part 4 (Supplies); Part 5 (Duties, records, reporting); Part 6 (Miscellaneous)
- Key Definitions (Section 2): “clinical research”, “clinical research material”, “auxiliary CRM”, “CTGT product”, “institutional review board”, “administer”, and related terms
- Notable Provisions: Import/export notifications and approvals; supply restrictions; labelling; traceability and record-keeping; adverse reaction reporting; defect reporting; recall; certificates of manufacturing/distribution standard; enforcement and offences
What Is This Legislation About?
The Health Products (Clinical Research Materials) Regulations 2016 (“CRM Regulations”) set out a regulatory framework for the manufacture, import, supply, handling, and oversight of “clinical research materials” in Singapore. In plain terms, they are designed to ensure that products used in human clinical research—such as investigational therapeutic products, placebos, and certain cell, tissue or gene therapy products—are controlled in a way that protects research subjects and supports regulatory confidence in the integrity of the research materials.
The Regulations operate alongside the Health Products Act and other research and healthcare regulatory regimes. They create specific exceptions, permissions, and obligations for clinical research materials, recognising that clinical research often involves products that are not yet authorised for general marketing. At the same time, the Regulations impose compliance duties similar in spirit to those found in broader health product regulation: traceability, proper labelling, record-keeping, reporting of safety issues, and recall mechanisms.
Practically, the CRM Regulations are most relevant to sponsors, manufacturers, importers, distributors, and healthcare institutions that supply or handle clinical research materials, as well as to any party responsible for administering those materials to research subjects under a protocol approved through the clinical research governance process.
What Are the Key Provisions?
1) Core definitions and scope (Part 1, Section 2)
The Regulations begin by defining key terms that determine when the CRM Regulations apply. The definition of “clinical research” is broad: it covers research involving human beings, whether or not it is a regulated clinical trial. “Clinical research material” is defined as specified health products manufactured, imported, or supplied for use in clinical research by way of administration to a subject in accordance with the protocol. This includes therapeutic products, placebos, and certain CTGT products (cell, tissue or gene therapy products), with additional nuance depending on CTGT classification and whether certain notices have been submitted under the CTGTP Regulations.
Two definitions are particularly useful for practitioners. First, “administer” is defined functionally: it includes oral administration, injection or other introduction into the body, and external application (with or without direct contact). This matters because the Regulations attach to “use … by way of administration” to subjects. Second, the Regulations define “institutional review board” as an independent body responsible for protecting rights, safety and wellbeing of subjects through review and continuing review of protocols and consent methods—linking the CRM Regulations to the ethics and governance infrastructure for human research.
2) Exceptions and regulatory gatekeeping for manufacture/import/supply (Part 2)
Part 2 addresses when clinical research materials are treated differently from ordinary health products under the Health Products Act. Section 3 provides “exceptions from Act” for clinical research materials, meaning that certain prohibitions or requirements in the parent Act may not apply in the same way, provided the CRM Regulations’ conditions are met.
Sections 4 to 7 establish procedural controls for cross-border movement and supply. These include:
- Notification of import (Section 4): importers must notify the Authority of imports of clinical research materials.
- Approval for psychotropic-containing consignments (Section 5): where consignments contain psychotropic substances, additional approval is required before import.
- Approval for export of certain clinical research materials (Section 6): export of specified categories requires approval.
- Notification of supply by manufacturer (Section 7): manufacturers must notify the Authority when supplying clinical research materials.
For lawyers advising sponsors or logistics teams, these provisions are often the first compliance checkpoint: they determine whether the product can legally enter Singapore and under what administrative steps.
3) Manufacture and import controls (Part 3, Section 8)
Part 3 focuses on the manufacture and import of clinical research materials. Section 8 requires that clinical research materials be manufactured and imported in accordance with the Regulations. While the extract provided does not reproduce the full text of Section 8, the structure of the Regulations indicates that manufacture/import is not “free-form”; it must meet regulatory expectations, including (as later provisions show) standards, traceability, and record-keeping.
4) Supply restrictions and labelling requirements (Part 4, Sections 9, 11–13)
Part 4 governs how clinical research materials may be supplied. Section 9 provides that clinical research materials may be supplied only as clinical research material—this is a critical limitation intended to prevent diversion into ordinary commercial channels.
Sections 11 and 12 address supply to subjects in relation to prescription-only or pharmacy-only medicines. In essence, they regulate how such medicines can be supplied to research subjects and how they may be administered under the protocol. Section 13 requires that clinical research material be properly labelled. Labelling is a cornerstone of safe handling: it supports correct identification, dosing, and traceability, and it reduces the risk of mix-ups in clinical settings.
5) Handling duties, traceability, records, and reporting (Part 5)
Part 5 contains the operational compliance obligations. Division 1 includes duties relating to dealing with clinical research materials (Section 14) and a specific traceability duty for CTGT products (Section 14A). Traceability is essential for recalls, investigations, and safety reporting. For CTGT products—often complex, high-value, and sensitive—Section 14A requires a “system of traceability” to track the product through the research supply chain.
Division 2 imposes record-keeping duties. Sections 15 to 18 require records of manufacture, receipt and supply, dealings with clinical research materials, and specify production and time requirements for keeping records. This is particularly important for audits and for responding to safety events. For practitioners, these provisions are often where compliance programs must be designed: standard operating procedures, batch/lot tracking, chain-of-custody logs, and retention schedules should align with the Regulations’ record categories and timing requirements.
Division 3 addresses safety and regulatory reporting. Section 19 requires notifications of unexpected serious adverse drug reactions. Section 19A imposes a duty to report defects. Section 20 provides for recall of clinical research materials. Together, these provisions create a safety net: when something goes wrong—unexpected serious reactions, product defects, or other safety concerns—the Regulations require timely reporting and enable regulatory recall actions.
6) Certificates of standards and enforcement (Part 6, Sections 21–24)
Part 6 includes certificates that support compliance with manufacturing and distribution standards. Section 21 provides for a certificate of manufacturing standard of clinical research materials, while Section 22 provides for a certificate of distribution standard. These certificates are typically used to demonstrate that the relevant parties meet the required quality and distribution controls.
Section 23 sets out enforcement requirements, and Section 24 creates offences. For counsel, the offences clause is crucial for risk assessment and for advising on compliance failures. Even where the extract does not list each offence in detail, the existence of an offences provision signals that breaches of key duties—notifications, approvals, labelling, traceability, record-keeping, reporting, and recall obligations—can attract criminal or regulatory consequences.
How Is This Legislation Structured?
The CRM Regulations are organised into six parts:
- Part 1 (General): citation/commencement (Section 1) and definitions (Section 2).
- Part 2 (Exceptions): exceptions from the Health Products Act for clinical research materials, plus procedural requirements for import/export/supply notifications and approvals (Sections 3–7).
- Part 3 (Manufacture and Import): the baseline rule for lawful manufacture and import (Section 8).
- Part 4 (Supplies): restrictions on how clinical research materials may be supplied, including supply only as clinical research material, rules for prescription-only/pharmacy-only medicines, and labelling requirements (Sections 9, 11–13).
- Part 5 (Duties): operational obligations covering dealing/traceability (Sections 14 and 14A), record-keeping (Sections 15–18), and safety/regulatory reporting including adverse reactions, defects, and recall (Sections 19–20).
- Part 6 (Miscellaneous): certificates of standards, enforcement requirements, and offences (Sections 21–24).
Who Does This Legislation Apply To?
The Regulations apply to persons who manufacture, import, supply, distribute, handle, or otherwise deal with “clinical research materials” in Singapore for use in clinical research by administration to human subjects under a protocol. This includes sponsors and their supply chain partners (manufacturers, importers, distributors), as well as healthcare service providers and institutions that receive and manage clinical research materials for use with subjects.
Because the Regulations impose duties on “dealing” with clinical research materials, record-keeping, traceability (especially for CTGT products), and reporting of adverse reactions and defects, they are relevant not only to commercial entities but also to research sites and clinical teams responsible for compliance with protocol-based administration and documentation.
Why Is This Legislation Important?
The CRM Regulations are important because they translate ethical and scientific clinical research requirements into enforceable product-control obligations. In a clinical research setting, the safety of subjects depends not only on protocol design and informed consent, but also on whether the right product is used, correctly labelled, traceable, and monitored for adverse events and defects.
From an enforcement and litigation perspective, the Regulations provide a clear compliance architecture: notifications and approvals for cross-border movement; supply limitations to prevent diversion; labelling and traceability duties to support safe use; record-keeping to enable auditability; and reporting/recall mechanisms to respond to safety signals. For practitioners, this means that compliance failures can be identified and attributed to specific stages of the supply chain and specific legal duties.
For day-to-day practice, the Regulations also influence contract drafting and operational governance. Sponsors and research sites typically need to allocate responsibilities for notifications, reporting, record retention, and recall readiness. The existence of certificates of manufacturing and distribution standards further affects vendor qualification and due diligence.
Related Legislation
- Health Products Act (Cap. 122D)
- Healthcare Services Act 2020
- Human Biomedical Research Act 2015
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (CTGTP Regulations)
- Medical Registration Act 1997
- Dental Registration Act 1999
Source Documents
This article provides an overview of the Health Products (Clinical Research Materials) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.